Dr. Peggi Angel, President
Peggi Angel is currently Assistant Professor at Medical University of South Carolina, where she works on technology advancements in MALDI IMS and application to cardiovascular disease and cancer. Peggi attended graduate school at the University of Georgia’s Complex Carbohydrate Research Center, graduating with a PhD in 2007. Her graduate research was on quantitative proteomics and N-linked glycoproteomics in mammalian development. After a postdoctoral study at Emory University focused on membrane proteomics of fetal alcohol syndrome, she won a competitive Postdoctoral Fellowship with the Systems-based Consortium for Organ Design and Engineering. With the Fellowship, she worked at Vanderbilt University on methods using MALDI IMS for developmental biology and participated in establishing the National Research Resource in Imaging Mass Spectrometry. Peggi has developed IMS methods for increasing sensitivity of protein detection from tissues, analysis and identification of lipids in negative mode at high spatial resolution, metabolomics on tissue and cell culture, targeted protein detection in tissues, proteomics of thin tissue sections, and on-tissue chemistries.
Dr. Christopher R. Anderton, President-Elect
Chris Anderton is currently a staff scientist at the Environmental Molecular Sciences Laboratory (EMSL), which is located on the Pacific Northwest National Laboratory (PNNL) campus. Chris received his BS in chemistry at the University of Colorado at Colorado Springs in 2005. He attained his PhD in chemistry at the University of Illinois at Urbana–Champaign in 2011, under Mary L. Kraft, where his graduate work focused on using secondary ion mass spectrometry (ToF-SIMS and NanoSIMS) in conjunction with atomic force microscopy and scanning electron microscopy for multi-technique correlative analysis of supported lipid membranes. Afterward, he received a US National Research Council Postdoctoral Associateship to work at the National Institute of Standards and Technology under Anne L. Plant, where he studied how eukaryotic cells respond to changes in the physicochemical properties of their extracellular environment, using force microscopy, fluorescence microscopy, and ToF-SIMS. In 2013, he joined the Mass Spectrometry Group at EMSL, where he is now leading the effort in developing new imaging mass spectrometry instrumentation and capabilities to elucidate chemical interactions occurring within microbial communities, soils, and the rhizosphere. In his free time, Chris loves to travel and explore the great outdoors.
Dr. Richard R. Drake, Past-President
Dr. Drake is a Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. He is an experienced protein biochemist and glycobiologist, with particular expertise in imaging MS of tumor tissues and biomarker discovery from clinical fluids. Dr. Drake received a B.S. from Centre College, Danville, KY, and a Ph.D. from the University of Kentucky, both in Biochemistry and Molecular Biology. Post-doctoral training in glycobiology was done with Alan Elbein at the University of Texas Health Science Center at San Antonio. Current efforts are in the large scale application of N-glycan MS imaging methods developed in his laboratory to prostate, pancreas, liver, and breast tumors. The goal is to develop glycan biomarkers associated with tumor, stroma and immune regions of tumors, in two and three dimensions.
Georgia Charkoftaki, MPharm, MSc, PhD, Secretary
Georgia Charkoftaki is currently an Associate Research Scientist at the Department of Environmental and Health Sciences, at Yale School of Public Health. She received her pharmacy degree from the University of Athens, Greece, where she also earned a MSc in drug delivery and a PhD in biopharmaceutics-pharmacokinetics. In August 2013 she moved to the University Colorado Denver to start a postdoc in clinical and translational science, focusing on kidney related diseases. Charkoftaki studied the pharmacokinetics of cyclophosphamide in patients undergoing dialysis and how Vitamin D affects drug metabolism in the kidneys, among other projects. At Yale, she has focused on studying the underlying pathology/mechanisms of the aldehyde dehydrogenases in various diseases, including cancer and neurodevelopmental disorders. She is using multi-omics approaches and she is an expert in studying the metabolome (metabolomics), lipidome (lipidomics), and utilizing tissue imaging mass spectrometry (IMS) with a special focus on MALDI.
Dr. Eric Solon, Treasurer
Eric Solon, Ph.D., is currently the Treasurer of the Imaging Mass Spectrometry Society and the Senior Director of Pharmacology and ADME at Madrigal Pharmaceuticals. Dr. Solon now directs and supports various preclinical and clinical studies to support the development of Madrigal Pharmaceuticals lead new drug candidate. Before joining Madrigal, Eric was the Senior Director and Fellow of Autoradiography in Pre-Clinical Drug Metabolism and Pharmacokinetics (DMPK) for QPS, LLC. Eric Joined QPS in 2002 as Director and business head of Autoradiography and Animal Resource units. Dr. Solon is an internationally recognized expert in the study of drug tissue distribution at the macro/micro level and has published >25 articles and 4 book chapters. Eric earned his Ph.D. Rutgers Univ.; and MS at Fairleigh Dickinson University while holding various positions in the Pathology Department of the Safety Evaluation Facility for Ciba-Geigy Pharmaceuticals (Novartis). Dr. Solon held various positions in DMPK as well as coordinating ADME studies and all QWBA tissue distribution/ADME studies at DuPont Pharmaceuticals, and Schering-Plough Corporation. He has expertise in managing lab operations, profit center operations, lab animal anatomy, physiology, necropsy & histology, gross pathology, pre-clinical ADME studies, and laboratory and computer validations. He served as President, President-elect, President Ex Officio, Webmaster, Secretary, and Councilor for the Society for Whole-Body Autoradiography (SWBA) and is an active member of the International Isotope Society.
Alison Scott, Counselor
Alison Scott is an assistant professor in the Department of Microbial Pathogenesis at the University of Maryland School of Dentistry in Baltimore, Maryland, adjunct in the Department of Microbiology & Immunology at the University of Maryland School of Medicine, and is a guest researcher at the Maastricht MultiModal Molecular Imaging Institute in the Netherlands. Alison completed her BS in biochemistry at Eastern Michigan University and earned her PhD in Molecular Microbiology & Immunology at the University of Maryland Baltimore. She has a diverse training background including working in CNS pharmacology at Pfizer Global Research & Development, adjuvant development at the Michigan Nanotechnology Institute for Medicine and Biological Sciences, and vaccine assessment at Aeras Global TB Vaccine Foundation. Her recent work has largely focused on applying imaging modalities, including imaging mass spectrometry, to understand host-pathogen interaction to instruct new therapeutic approaches to infection and immunity. Additionally, she has developed methods for detection of complex microbial glycolipids from infected tissues, expanding the possibilities for studies of Gram-negative infections and joining her two favorite topics: endotoxin structure and imaging mass spectrometry. Alison also serves as the Treasurer on the International Endotoxin and Innate Immunity Society Board.
Julia Laskin, Counselor
Julia Laskin is a William F. and Patty J. Miller Professor of Analytical Chemistry at Purdue University. Her research is focused on the development of instrumentation and methods for quantitative imaging of biological samples using nanospray desorption electrospray ionization (nano-DESI) mass spectrometry. The goal of these developments is to enhance the spatial resolution, sensitivity, chemical specificity, throughput, and dynamic range of imaging experiments and to provide the most detailed molecular snapshots of biological systems. Before joining Purdue, she was a scientist at Pacific Northwest National Laboratory (2002-2017).
Lisa Cazares, Counselor
Lisa Cazares is the Director of Dynamic Omics within the Discovery Sciences function, at AstraZeneca R&D in Gaithersburg, MD. Dr. Cazares previously worked at the U.S. Army Medical Research Institute of Infectious Diseases with a focus on metabolomics by MALDI FT-ICR tissue imaging. She has over 20 years of experience in proteomics and mass spectrometry techniques including protein profiling, MALDI mass spectrometry tissue imaging, as well as multi-dimensional ESI-LC-MS/MS for large-scale protein expression profiling. Dr. Cazares research at AstraZeneca focuses on the use of mass spectrometry based methods for the discovery of novel drug targets as well as diagnostic, predictive and prognostic biomarkers in tissues and biofluids. Her lab is currently optimizing the use of single-cell/low input proteomics and phospho-proteomics in conjunction with metabolomics profiling and imaging in FFPE and fresh frozen tissues.
Bingming Chen, Counselor
Dr. Bingming Chen is an associate principal scientist at Merck. She is part of the ADME group of the preclinical development department. She is investigating the tissue distribution of therapeutic agents in preclinical species through the application of mass spectrometry imaging techniques. Prior to Merck, she graduated from Dr. Lingjun Li’s lab at University of Wisconsin-Madison in 2017 with a doctoral degree in pharmaceutical sciences. She also got her Bachelor’s degree from University of Wisconsin-Madison and recently finished her Master of Business Administration degree at the Gies College of Business – University of Illinois Urbana-Champaign. She has published 29 peer-reviewed articles in the areas of mass spectrometry imaging, quantitative glycomics and biomolecule characterization.
Coming Soon, Webmaster
New webmaster coming soon.